

## Special Issue

# Complexity and Challenges in the Diagnosis and Treatment of Chronic Respiratory Diseases

### Message from the Guest Editor

Humans are exposed to numerous infections, toxins, and irritants daily, resulting in persistent inflammation. Chronic respiratory diseases (CRDs) pose a major public health problem, with an estimated 3.9 million deaths in 2017, accounting for 7% of all deaths worldwide. Chronic lung disease (COPD) and asthma are the most common respiratory conditions, but others, such as pneumoconiosis, interstitial lung disease, fibrosis, pulmonary sarcoidosis, and lung cancer, are also global public health concerns. The challenges in the diagnosis and management of patients with CRDs require a multidisciplinary and individualized approach to care, including an in-depth understanding of the complex molecular basis, new biomarker detection, and implementation of combination/personalized treatments. We seek research papers that will consolidate our understanding of this field. The Special Issue will publish full research articles and comprehensive reviews on all aspects related to the theme of CRD, from its molecular and genetic factors to novel prediction, diagnostic, and therapeutic approaches, are welcome.

### Guest Editor

Dr. Magdalena Radecka

Institute of Physical Chemistry of the Polish Academy of Sciences, 01-224 Warsaw, Poland

### Deadline for manuscript submissions

closed (30 April 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/191689](https://mdpi.com/si/191689)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).